2011, the year of PrEP. In less than 18 months 6 clinical trials investigating the potential use of HIV antiretrovirals (ARV) for the prevention of HIV acquisition have rocked the HIV prevention world. First it was the South African CAPRISA announcing in July 2010
A survey conducted by SIGMA Research is the first to provide some insights into the prospective attitude of gay and bisexual men towards PrEP in England following the release of the iPrEX study in 2010. Knowledge of PrEP, its acceptability, dosage preference and potential effects
New HIV Prevention Technologies (NPTs) were presented and discussed during a seminar on the “Social Aspects of HIV prevention technologies: Translating research into policy & practice” organised by The African Health Policy Network, with the aim to address key research questions affecting African communities
Closure of oral Tenofovir arm in VOICE Pre-Exposure Prophylaxis trial: PrEP as a “niche intervention”?
The Microbicides Trial Network (MTN) announced yesterday that its VOICE (Vaginal and Oral Interventions to Control the Epidemic, MTN003) HIV Pre-Exposure Prophylaxis (PrEP) prevention study will discontinue the daily oral tenofovir arm of the trial. The decision follows an interim review of the trial’s data
Roger J. Tatoud (Updated 18 May 2011) – Another month and another HIV prevention trial ending prematurely; but this time it is because the study was showing very encouraging outcomes. The trial named HPTN052 and conducted by the HIV Prevention Trial Network was designed to